Serum fructosamine in the assessment of glycaemic status in patients with sickle cell anaemia

Yahaya, IA; Isah, HS; Anaja, P. O.

doi:10.4103/1117-1936.180490

Cited by 5 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In patients with sickle cell disease and DM, HbA1c is not reliable for the diagnosis of DM and monitoring of glycemic control, while serum glucose measurements should be used [48]. Furthermore, the levels of serum fructosamine have been used for the monitoring of those patients [49][50][51]. Metformin might reduce the occurrence of hospitalization rates in SCD individuals and vaso-occlusive episodes [52].…”

Section: Impaired Glucose Metabolism and Diabetes Mellitusmentioning

confidence: 99%

Endocrinopathies in Hemoglobinopathies: What Is the Role of Iron?

Evangelidis,

Venou,

Fani

et al. 2023

IJMS

View full text Add to dashboard Cite

Hemoglobinopathies, including β-thalassemia and sickle cell disease (SCD), are common genetic blood disorders. Endocrine disorders are frequent manifestations of organ damage observed mainly in patients with β-thalassemia and rarely in SCD. Iron overload, oxidative stress-induced cellular damage, chronic anemia, and HCV infection contribute to the development of endocrinopathies in β-thalassemia. The above factors, combined with vaso-occlusive events and microcirculation defects, are crucial for endocrine dysfunction in SCD patients. These endocrinopathies include diabetes mellitus, hypothyroidism, parathyroid dysfunction, gonadal and growth failure, osteoporosis, and adrenal insufficiency, affecting the quality of life of these patients. Thus, we aim to provide current knowledge and data about the epidemiology, pathogenesis, diagnosis, and management of endocrine disorders in β-thalassemia and SCD. We conducted a comprehensive review of the literature and examined the available data, mostly using the PubMed and Medline search engines for original articles. In the era of precision medicine, more studies investigating the potential role of genetic modifiers in the development of endocrinopathies in hemoglobinopathies are essential.

show abstract

Section: Impaired Glucose Metabolism and Diabetes Mellitusmentioning

confidence: 99%

Endocrinopathies in Hemoglobinopathies: What Is the Role of Iron?

Evangelidis,

Venou,

Fani

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

Abnormal glucose metabolism in heterozygous mutant mice for a type I receptor required for BMP signaling

Scott

Ray

Ward

et al. 2009

Genesis

View full text Add to dashboard Cite

Summary BMPRIA and its high-affinity ligand BMP4 have recently been shown to be expressed in the β-cells of the pancreas. Here, we report the abnormalities of heterozygous mice for Bmpr1a in glucose metabolism during the course of intraperitoneal glucose tolerance test. The heterozygous mice had increased blood glucose levels throughout the first 2.5 h after the administration of glucose. Analysis of glucose-stimulated insulin secretion (GSIS) indicates that insulin secretion in the heterozygous mice is compromised, and induction of secreted insulin by stimulation is substantially lower compared with the wild-type controls. No apparent abnormalities in pancreas, thyroid, and liver were seen upon histological examination. Real-time PCR results of selected genes showed an increase in the mRNA level of Ins1 and Ins2 in the heterozygous group. These results indicate that the glucose-sensing pathway in these heterozygous mice is altered because of the heterozygosity in Bmpr1a. Together, our data suggest that BMP signaling through BMPRIA plays an important role in glucose metabolism and possibly working through the GSIS pathway. genesis 00:1–7, 2009.

show abstract